A Phase 3 interventional study of Denufosol tetrasodium Inhalation Solution in Cystic Fibrosis, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2015-11-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cystic Fibrosis by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Cystic Fibrosis · Merck & Co., Inc.
Among the 10 studies in Cystic Fibrosis by Merck & Co., Inc, this one is the 3rd largest by enrollment, is the only one that started in 2009, is one of 3 in phase 3, and was the 8th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 10 studies in Cystic Fibrosis by Merck & Co., Inc is open now. The open studies under Cystic Fibrosis, anywhere →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 5 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 3
First in 2001; this study’s year is marked. 1 started in 2009.
This study's enrollment of 308 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 68 across the 10 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.
Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Cystic Fibrosis by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to obtain data on the potential of long-term treatment with denufosol to improve the clinical course of CF lung disease in patients with mildly impaired lung function and to provide CF patients who completed study 08-110 continued access to denufosol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Denufosol tetrasodium Inhalation Solution
60 mg by oral inhalation three times daily
Rate of change in lung function, as measured by change in FEV1
Time frame: 160 Weeks
Change in absolute FEV1 from baseline
Time frame: Weeks 12, 24, 36, 48, 72, 96, 120, 144, and 160
Change in FEV1 percent predicted value from baseline
Time frame: Weeks 12, 24, 36, 48, 72, 96, 120, 144, and 160
Change in FEF25%-75% and forced vital capacity (FVC) from baseline
Time frame: Weeks 12, 24, 36, 48, 72, 96, 120, 144, and 160
Incidence of pulmonary exacerbations
Time frame: 160 Weeks
Changes in Pseudomonas aeruginosa status
Time frame: 160 Weeks
Number of days of intravenous (IV) antibiotic use for a respiratory complaint
Time frame: 160 Weeks
Incidence of hospitalizations/Emergency room (ER) visits for a respiratory complaint
Time frame: 160 Weeks
Number of days hospitalized for a respiratory complaint
Time frame: 160 Weeks
Incidence of treatment emergent adverse events (AEs), serious adverse events (SAEs) and withdrawals due to AEs
Time frame: 160 Weeks
Incidence of patients with significant decrease in absolute FEV1 at any visit from baseline
Time frame: 160 Weeks
Changes in physical exam findings including height, weight, and body mass index from baseline
Time frame: Weeks 48, 96, and 160
Changes in hematology, serum chemistry, and urinalysis parameters from baseline
Time frame: Weeks 24, 48, 72, 96, 120, 144, and 160
Incidence of hospitalizations/ER visits
Time frame: 160 Weeks
Incidence of early discontinuations from the study
Time frame: 160 Weeks
No study locations are listed for this record.
The record gives a start of Feb 2009, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.